These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30024493)

  • 21. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
    Borisov AS; Bamrah Morris S; Njie GJ; Winston CA; Burton D; Goldberg S; Yelk Woodruff R; Allen L; LoBue P; Vernon A
    MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(25):723-726. PubMed ID: 29953429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial.
    Chan PC; Yang CH; Chang LY; Wang KF; Lu BY; Lu CY; Shao PL; Hsueh PR; Fang CT; Huang LM
    Int J Tuberc Lung Dis; 2012 May; 16(5):633-8. PubMed ID: 22410137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Latent tuberculosis treatment completion rates from prescription drug administrative data.
    Plourde PJ; Basham CA; Derksen S; Schultz J; McCulloch S; Larcombe L; Kinew KA; Lix LM
    Can J Public Health; 2019 Dec; 110(6):705-713. PubMed ID: 31297736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.
    Njie GJ; Morris SB; Woodruff RY; Moro RN; Vernon AA; Borisov AS
    Am J Prev Med; 2018 Aug; 55(2):244-252. PubMed ID: 29910114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates.
    Bock NN; Rogers T; Tapia JR; Herron GD; DeVoe B; Geiter LJ
    Chest; 2001 Mar; 119(3):833-7. PubMed ID: 11243965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
    Villarino ME; Scott NA; Weis SE; Weiner M; Conde MB; Jones B; Nachman S; Oliveira R; Moro RN; Shang N; Goldberg SV; Sterling TR; ;
    JAMA Pediatr; 2015 Mar; 169(3):247-55. PubMed ID: 25580725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Completion rates of treatment for latent tuberculosis infection in Quebec, Canada from 2006 to 2010.
    Rivest P; Street MC; Allard R
    Can J Public Health; 2013 May; 104(3):e235-9. PubMed ID: 23823888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isoniazid and Rifapentine Treatment Eradicates Persistent
    Foreman TW; Bucşan AN; Mehra S; Peloquin C; Doyle LA; Russell-Lodrigue K; Gandhi NR; Altman J; Day CL; Ernst JD; Blumberg HM; Rengarajan J; Kaushal D
    Am J Respir Crit Care Med; 2020 Feb; 201(4):469-477. PubMed ID: 31647877
    [No Abstract]   [Full Text] [Related]  

  • 30. Improved treatment completion with shorter treatment regimens for latent tuberculous infection.
    Macaraig MM; Jalees M; Lam C; Burzynski J
    Int J Tuberc Lung Dis; 2018 Nov; 22(11):1344-1349. PubMed ID: 30355415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
    Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
    J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
    Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
    Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
    Holland DP; Sanders GD; Hamilton CD; Stout JE
    PLoS One; 2011; 6(7):e22276. PubMed ID: 21789248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
    Fresard I; Bridevaux PO; Rochat T; Janssens JP
    Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
    Haas MK; Aiona K; Erlandson KM; Belknap RW
    Clin Infect Dis; 2021 Nov; 73(9):e3459-e3467. PubMed ID: 32915203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
    Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ
    Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study.
    Yang H; Yang Y; Hu ZD; Xia L; Liu XH; Yu X; Ma JY; Li T; Lu SH
    PLoS One; 2021; 16(6):e0253159. PubMed ID: 34115804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors That Influence Treatment Completion for Latent Tuberculosis Infection.
    Eastment MC; McClintock AH; McKinney CM; Narita M; Molnar A
    J Am Board Fam Med; 2017; 30(4):520-527. PubMed ID: 28720633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of latent tuberculosis infection: An update.
    Lobue P; Menzies D
    Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.